MSB

3.33%

$1.40 mesoblast limited

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-328

First 328 Last

Share
Profile

Follow
Broderick

349 Posts.

7

17/11/20

12:03

Post #: 48927293
Share

Originally posted by dontfollowme: ↑

SIR-spheres = Was classed as a "device" so took an easier path thru the FDA minefield, compared to "drug" pathways. Got approved for CEmark TGA and FDA without too many hiccups.
Cell based therapy a new realm which the FDA have showed they seem somewhat adverse too.......understanding?? ODAC was convinced by Ryoncil cept for Hinrich who appears to have the FDA's ear/pocket.
FDA were correct in questioning single arm trial, but endorsed it previously enough to give BLA submission, Did not indicate that 69% survival success from Phase 3 in children would not be enough to sway he stats for efficacy till the final hurdle....then pulled the rug out.
FDA seem to be treating it like the Rosetta stone......no compredo. FDA adverse to gene/cell based treatment approval.
Other market approval strategy may work instead...don't know why this has not been addressed by the company already for CEmark/TGA for Ryoncil, new capital funds should already be earmarked for this......why not? I would ask this question at AGM.
Occurence of Leukemia is worldwide lets focus elsewhere and leave the FDA holding the empty cot so to speak.
Why not target 1st worl economies with more forward thinking heathcare? Why not China/Asia/Canada/European Union....even Russia. Get some alternatives happening for market in roads...don't pin hopes all in on a dinosaur riddled archaic approval system which has already higlighted that even with expert advice on proven treatment without side effects in a feild where there is little alternative cept death. They hum and haa and go now bout we start from scratch again.........fark that.
If Type A rejected, no accelerated pathway is agreed to I feel its time to pull up the stumps for USA and present a new direction.
Either the Pharma industry there see's disruptive treatment a real threat to their script based gravy train of ongoing cashcows or the FDA is to Prolife conservative mindset to introduce any new gene/cell treatments. ok vented.
Market down...screen blank KZA was off to the races then............halted. Pah!!
Also forgot to mention MSB recieved huge accolades from the peer voted Biotech awards - Fierce, no avail.

Expand

Very True, The FDA are certainly in no hurry to approve.
On another issue Mesoblast stated very clearly at the start of this year that trial results for back pain and the heart would be released mid year.
Well we a four months out and nothing, there was conjecture that the results would be announced at the American heart association meeting?
Well nothing!

MSB Price at posting: $3.28 Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched and most discussed stocks this week

Trump is President Again: What Does This Mean for Crypto?

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

IMU

Imugene kicks off Australian trial for blood cancer treatment

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

There are more pages in this discussion • 65 more messages in this thread...

First 328 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.40		Change 0.045(3.33%)		Mkt cap ! $1.592B

Open	High	Low	Value	Volume
$1.35	$1.42	$1.33	$3.802M	2.753M

Buyers (Bids)

No.	Vol.	Price($)
2	23940	$1.39

Sellers (Offers)

Price($)	Vol.	No.
$1.40	22571	2

View Market Depth

No.	Vol.	Price($)
1	13940	1.390
1	14000	1.385
2	15350	1.370
2	20000	1.355
2	2400	1.350

Price($)	Vol.	No.
1.395	22571	2
1.400	108300	3
1.405	39000	3
1.410	1430	1
1.415	67966	3

Last trade - 16.10pm 08/11/2024 (20 minute delay)

MSB (ASX) Chart

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-328

HotCopper Highlights: Your most watched and most discussed stocks this week

Trump is President Again: What Does This Mean for Crypto?

Universal Biosensors flat despite fresh deal with US medical product distributor

Imugene kicks off Australian trial for blood cancer treatment

Flynn Gold reaches milestone exploration target for Golden Ridge

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-328

Top Stories

HotCopper Highlights: Your most watched and most discussed stocks this week

Trump is President Again: What Does This Mean for Crypto?

Universal Biosensors flat despite fresh deal with US medical product distributor

Imugene kicks off Australian trial for blood cancer treatment

Flynn Gold reaches milestone exploration target for Golden Ridge

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News